Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study

The Lancet

Volumn 394, Issue 10205, 2019, Pages 1254-1263

  Santema, Bernadet T ^a   Ouwerkerk, Wouter ^b,c   Tromp, Jasper ^a,b   Sama, Iziah E ^a   Ravera, Alice ^a,d   Regitz Zagrosek, Vera ^e   Hillege, Hans ^a   Samani, Nilesh J ^f,g   Zannad, Faiez ^h   Dickstein, Kenneth ⁱ   Lang, Chim C ^j   Cleland, John G ^k,l   Ter Maaten, Jozine M ^a   Metra, Marco ^d   Anker, Stefan D ^m   van der Harst, Pim ^a   Ng, Leong L ^f,g   van der Meer, Peter ^a   van Veldhuisen, Dirk J ^a   Meyer, Sven ⁿ   Lam, Carolyn S P ^a,b,o   Richards, Arthur Mark ^o   Anand, Inder ^o   Hung, Chung Lieh ^o   Ling, Lieng Hsi ^o   Liew, Houng Bang ^o   Narasimhan, Calambur ^o   Ngarmukos, Tachapong ^o   Park, Sang Weon ^o   Reyes, Eugenio ^o   Siswanto, Bambang Budi ^o   Shimizu, Wataru ^o   Zhang, Shu ^o   Voors, Adriaan A ^a   more..

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b DEPARTMENT OF CARDIOLOGY   (Singapore)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY OF BRESCIA   (Italy)

^e DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^f UNIVERSITY OF LEICESTER   (United Kingdom)

^g GLENFIELD HOSPITAL   (United Kingdom)

^h UNIVERSITY HOSPITAL OF NANCY   (France)

ⁱ STAVANGER UNIVERSITY HOSPITAL   (Norway)

^j UNIVERSITY OF DUNDEE   (United Kingdom)

^k ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^l UNIVERSITY OF GLASGOW   (United Kingdom)

^m CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁿ UNIVERSITY OF OLDENBURG   (Germany)

^o NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGE DISTRIBUTION; AGED; ALL CAUSE MORTALITY; ARTICLE; BODY MASS; BODY SURFACE; BODY WEIGHT; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE REGISTRY; DOSE CALCULATION; DRUG DOSE TITRATION; DRUG EFFICACY; EUROPE; FEMALE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; SEX DIFFERENCE; VALIDATION PROCESS; DRUG EFFECT; HEART FAILURE; HEART STROKE VOLUME; MORTALITY; SEX FACTOR;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HEART FAILURE; HUMANS; MALE; PROSPECTIVE STUDIES; SEX FACTORS; STROKE VOLUME;

EID: 85072780741     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(19)31792-1     Document Type: Article

References (30)

1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891–975.
2. Eugene AR. Metoprolol dose equivalence in adult men and women based on gender differences: pharmacokinetic modeling and simulations. Med Sci 2016; 4: 18.
3. Eugene AR. Gender based dosing of metoprolol in the elderly using population pharmacokinetic modeling and simulations. Int J Clin Pharmacol Toxicol 2016; 5: 209–15.
4. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2009; 48: 143–57.
5. Whitley H, Lindsey W. Sex-based differences in drug activity. Am Fam Physician 2009; 80: 1254–48.
6. Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov 2006; 5: 425–38.
7. Rosano GM, Lewis B, Agewall S, et al. Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC. Eur Heart J 2015; 36: 2677–80.
8. Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 1999; 66: 594–601.
9. Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 2005; 26: 1585–95.
10. Voors AA, Anker SD, Cleland JG, et al. A systems biology study to tailored treatment in chronic heart failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. Eur J Heart Fail 2016; 18: 716–26.
11. Ouwerkerk W, Voors AA, Anker SD, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 2017; 38: 1883–90.
12. Lam CS, Anand I, Zhang S, et al. Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry. Eur J Heart Fail 2013; 15: 928–36.
13. Voors AA, Ouwerkerk W, Zannad F, et al. Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. Eur J Heart Fail 2017; 19: 627–34.
14. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Nutrition 1989; 5: 3.
15. Halloran M, Berry D. Statistical models in epidemiology, the environment, and clinical trials. New York, NY: Springer-Verlag, 2000.
16. Wal WM, Geskus RB. Ipw: an r package for inverse probability weighting. J Stat Softw 2011; 43: 1–21.
17. Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc Ser B 1994; 58: 267–88.
18. Hastie TJ. Generalized additive models. Pacific Grove, CA: Wadsworth & Brooks/Cole, 1992.
19. Bonetti M, Gelber RD. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 2000; 19: 2595–609.
20. Bonetti M, Gelber RD. Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 2004; 5: 465–81.
21. Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 2003; 35: 99–106.
22. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525–33.
23. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347: 1403–11.
24. van Veldhuisen DJ, Rienstra M, van der Meer P. Value of digoxin in patients with heart failure: new pieces to the puzzle. Eur J Heart Fail 2018; 20: 1146–47.
25. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374: 1840–48.
26. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100: 2312–18.
27. EUGenMed Cardiovascular Clinical Study Group, Regitz-Zagrosek V, Oertelt-Prigione S, et al. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. Eur Heart J 2016; 37: 24–34.
28. Linde C, Cleland JGF, Gold MR, et al. The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis. Eur J Heart Fail 2018; 20: 780–91.
29. Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 2018; 72: 351–66.
30. Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019; 393: 61–73.